EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A cerebellar degeneration‐related protein 2‐like cell‐based assay for anti‐Yo detection in patients with paraneoplastic cerebellar degeneration

Kjell Inge Erikstad, Ida Herdlevaer iD, Elise Peter, Mette Haugen, Cecilie Totland, Christian Vedeler

European Journal of Neurology · 2023

DOI: 10.1111/ene.15786 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Kjell Inge Erikstad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Cerebellar Diseases, Paraneoplastic Cerebellar Degeneration. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Commercially available tests for Yo antibody detection have low specificity for paraneoplastic cerebellar degeneration (PCD) because these assays use cerebellar degeneration‐related protein 2 (CDR2) as the antigen, not CDR2‐like (CDR2L). We aimed to test the hypothesis that use of a CDR2L cell‐based assay (CBA), as an additional screening technique, would increase the accuracy of Yo‐PCD diagnosis.

Methods

An in‐house CBA to test for anti‐CDR2L antibodies was developed and used to screen sera from 48 patients with confirmed anti‐Yo‐associated PCD. Fifteen non‐Yo PCD patients, 22 patients with ovarian cancer without neurological syndromes, 50 healthy blood donors, 10 multiple sclerosis, 15 Parkinson's disease, and five non‐paraneoplastic ataxic patients were included as controls. Sera were also tested by western blot analysis using recombinant CDR2 and CDR2L proteins developed in house, by the commercially available line immunoassays from Ravo Diagnostika and Euroimmun, and by the CDR2 CBA from Euroimmun.

Results

The CDR2L CBA identified all 48 patients with Yo‐PCD. No CDR2L CBA reaction was observed in any of the control sera. The western blot technique had lower sensitivity and specificity as sera from eight and six of the 48 Yo‐PCD patients did not react with recombinant CDR2 or CDR2L, respectively.

Conclusions

The CDR2L CBA is highly reliable for identification of Yo‐PCD. Although our findings indicate that, currently, the combination of CDR2 and CDR2L yields the most reliable test results, it remains to be evaluated if a test for single anti‐CDR2L positivity will serve as a sufficient biomarker for Yo‐PCD diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebellar DiseasesParaneoplastic Cerebellar DegenerationHumansAutoantibodiesNerve Tissue ProteinsRecombinant ProteinsAntibodies, NeoplasmAutoantigens

Stichwörter der Autor:innen

anti-Yocell-based assaycerebellar degeneration-related proteinsparaneoplastic cerebellar degeneration

Substanzen

AutoantibodiesNerve Tissue ProteinsRecombinant Proteinsanti-Yo autoantibodiesAntibodies, NeoplasmCDR2L antigen, humanAutoantigensCDR2 protein, human

Autor:innen und Institutionen

  • Department of Clinical Medicine, University of Bergen, Bergen, Norway.
  • Neuro-SysMed - Centre of Excellence for Experimental Therapy in Neurology, Departments of Neurology and Clinical Medicine, Bergen, Norway.
  • Department of Neurology, Haukeland University Hospital, Bergen, Norway.
  • Synaptopathies and Autoantibodies (SynatAc) Team, Institut NeuroMyoGène-MeLiS, INSERM U1314/CNRS UMR 5284, Université de Lyon, Lyon, France.
  • French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon, University of Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France.

ORCID-Profile: Ida Herdlevaer

Zitieren

APA

Erikstad, K. I., Herdlevaer, I., Peter, E., Haugen, M., Totland, C., & Vedeler, C. (2023). A cerebellar degeneration‐related protein 2‐like cell‐based assay for anti‐Yo detection in patients with paraneoplastic cerebellar degeneration. European Journal of Neurology. https://doi.org/10.1111/ene.15786

Vancouver

Erikstad KI, Herdlevaer I, Peter E, Haugen M, Totland C, Vedeler C. A cerebellar degeneration‐related protein 2‐like cell‐based assay for anti‐Yo detection in patients with paraneoplastic cerebellar degeneration. European Journal of Neurology. 2023. doi:10.1111/ene.15786

BibTeX
@article{Erikstad2023,
  author = {Erikstad, Kjell Inge and Herdlevaer, Ida and Peter, Elise and Haugen, Mette and Totland, Cecilie and Vedeler, Christian},
  title = {A cerebellar degeneration‐related protein 2‐like cell‐based assay for anti‐Yo detection in patients with paraneoplastic cerebellar degeneration},
  journal = {European Journal of Neurology},
  year = {2023},
  doi = {10.1111/ene.15786}
}
Kostenlos starten →